托法替布单药与联合治疗类风湿关节炎的安全性与疗效维持:开放标签长期扩展研究的汇总数据分析
该事后分析汇总了两项开放标签长期扩展研究(ORAL Sequel 与 NCT00661661)的数据,纳入4967例接受托法替布治疗的患者,评估单药或联合治疗及方案切换患者的疗效与安全性。单药组87.8%、联合组82.0%的患者维持原方案,疗效维持至第48个月并持续至第72个月,安全性在96个月内保持一致。
要点
- 4967例中35.4%起始单药、64.6%起始联合治疗,单药组87.8%与联合组82.0%维持原方案。
- 托法替布单药或联合治疗的疗效维持至第48个月并持续至第72个月。
- 96个月内安全性保持一致,5 mg与10 mg每日两次的不良事件发生率置信区间重叠。
核心结论
- 托法替布单药或联合治疗的疗效维持至第48个月并持续至第72个月,治疗方案切换极少,安全性在96个月内保持一致。
研究设计与样本
- 事后分析汇总两项开放标签长期扩展研究(ORAL Sequel(NCT00413699,进行中,数据收集截至2016年1月14日)与NCT00661661)的数据,纳入参与合格索引研究的患者,共4967例接受托法替布治疗。
- 安全性评估覆盖96个月。
主要发现
- 4967例治疗患者中,35.4%起始托法替布单药治疗,64.6%起始联合治疗,2.6%为单药转联合切换者,7.1%为联合转单药切换者,多次切换者被排除。
- 起始单药治疗者中87.8%(1543/1757)和起始联合治疗者中82.0%(2631/3210)在整个研究期间维持同一方案,疗效得以维持。
- 托法替布5 mg与10 mg每日两次的严重不良事件发生率,单药治疗分别为9.42与8.41,联合治疗分别为8.36与10.75;因不良事件停药的发生率,单药治疗分别为7.13与6.06,联合治疗分别为7.82与8.06(置信区间重叠)。
- 单药转联合与联合转单药切换者中,切换后30天内因不良事件停药者分别占0.8%与0.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. This post hoc analysis evaluated patients receiving tofacitinib monotherapy or combination therapy, as well as those who switched from monotherapy to combination therapy (mono→combo) or vice versa (combo→mono) in long-term extension (LTE) studies. METHODS: Data were pooled from open-label LTE studies (ORAL Sequel (NCT00413699; ongoing; data collected 14 January 2016) and NCT00661661) involving patients who participated in qualifying index studies. Efficacy outcomes included American College of Rheumatology 20/50/70 rates, change from baseline in Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4(ESR)), Clinical Disease Activity Index (CDAI) and Health Assessment Questionnaire-Disability Index and DAS28-4(ESR) and CDAI low disease activity and remission. Safety was evaluated over 96 months. RESULTS: Of the 4967 patients treated, 35.4% initiated tofacitinib monotherapy, 64.6% initiated combination therapy, 2.6% were mono→combo switchers and 7.1% were combo→mono switchers. Patients who switched multiple times were excluded. Of those who initiated monotherapy and combination therapy, 87.8% (1543/1757) and 82.0% (2631/3210), respectively, remained on the same regimen throughout the study; efficacy was maintained. Incidence rates (IRs) for serious adverse events with tofacitinib 5 mg and 10 mg twice daily, respectively, were 9.42 and 8.41 with monotherapy and 8.36 and 10.75 with combination therapy; IRs for discontinuations due to AEs were 7.13 and 6.06 with monotherapy and 7.82 and 8.06 with combination therapy (overlapping CIs). For mono→combo and combo→mono switchers, discontinuations due to AEs were experienced by 0.8% and 0.9%, respectively, within 30 days of switching. CONCLUSION: Tofacitinib efficacy as monotherapy or combination therapy was maintained through month 48 and sustained to month 72, with minimal switching of treatment regimens. Safety was consistent over 96 months. CLINICAL TRIAL REGISTRATION: NCT00413699 (Pre-results) and NCT00661661 (Results).
引用
- Fleischmann R, Wollenhaupt J, Takiya L, et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017. PMID: 29435359. doi:10.1136/rmdopen-2017-000491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。